Pulmonary Arterial Hypertension Treatment Market

Pulmonary Arterial Hypertension Treatment Market: Lack of Treatment Awareness, Inadequate R&D, & Frequent Drug Rejection Post Clinical Trial to Hamper Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Introduction

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

According to Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), the global prevalence of pulmonary arterial hypertension treatment market is projected to be 100,000 – 200,000—which accounts for 15 - 50 patients per million of the population.

Expert analysis into the subject has reveals that due to the rarity of the disease and the complexity of diagnosing it, only a small fraction of patients with PAH are being treated. Due to which, the Global Pulmonary Arterial Hypertension Treatment market is anticipated to grow at a sluggish CAGR of 2.5% over the forecast period 2018-2028.

Endothelin Receptor Antagonists (ERAs) to lead the Market among Drugs; SGC Stimulators to Capture Market by the End of 2028 Owing to Drug Effectiveness

According to expert analysis, the global pulmonary arterial hypertension treatment market is anticipated to grow at a steady rate. Based on drug type, the global pulmonary arterial hypertension treatment market is segmented into vasodilators, Phosphodiesterase 5 (PDE 5) inhibitors, Endothelin receptor Antagonists (ERA), Soluble guanylate cyclase (SGC) stimulator with ERAs accounting for the highest market share in terms of value.

However, SGC stimulator drug- is expected to witness relatively higher growth rates in terms of value in the global pulmonary arterial hypertension treatment market, due to its positive results. According to research Riociguat is the first SGC stimulator that has entered clinical development- showing significantly results in treating pulmonary vascular haemodynamics and increases exercise ability in patients with PAH. 

Lack of Awareness, Slow Drug R&D, and Unsuccessful Clinical Trials Restraining the Growth of Global Pulmonary Arterial Hypertension Treatment Market

Rising prevalence of pulmonary arterial hypertension has witnessed increased adoption of medicinal treatment of PAH, healthcare spending, rise in awareness, and huge drug pipeline. However, several factors have hampered the growth of global pulmonary arterial hypertension treatment market.

Currently, several forms of medication in the global prevalence of pulmonary arterial hypertension treatment market are adopted by people with PAH, but unfortunately no treatment has significantly improved survival.

For instance, Ruvise (imatinib)-used for adults as add-on therapy for the treatment PAH, is continually questioned for its efficacy. Treatment with Ruvise should only be initiated in patients who are not showing signs of rapid disease progression.

Ruvise has been studied only in combination with two or more conventional PAH-specific therapies. Efficacy has been shown in patients suffering from idiopathic PAH, heritable PAH and in PAH associated with connective tissue disease. Medical research has also shown an unexplained higher risk of subdural haemorrhage associated with imatinib use.

Additionally, slow productivity of R&D in the global pulmonary arterial hypertension treatment market owing to high diagnosis and treatment cost, termination of drugs by major players during clinical trials, unawareness about presence of pulmonary arterial hypertension among patients are some of the factors which are hampering the growth of this market.

Lastly, expiry of patents of major PAH drugs will lead to generic versions of these drugs being sold at 60% to 70% lower prices than that of the present branded drugs- projected to pose a challenge for the growth the global pulmonary arterial hypertension treatment market.

Market Segmentation

The global pulmonary arterial hypertension treatment market is segmented on the basis of drug type into:

  • Vasodilators
  • Phosphodiesterase 5 (PDE 5) inhibitors
  • Endothelin receptor Antagonists (ERA)
  • Soluble guanylate cyclase (SGC) stimulator

The report also has a ‘market dynamics’ section, wherein FMI’s analysis key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global pulmonary arterial hypertension treatment market.

The report analyses the market on the basis of the distribution channel and presents an in-depth analysis of:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Next up, the report analyses the market on the basis of regions:

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Western Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • BENELUX countries
    • Nordic Countries
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Rest of Eastern Europe
  • Asia Pacific
    • India
    • Australia & New Zealand
    • Rest of APECJ
  • China
  • Japan
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Pulmonary Arterial Hypertension Treatment Market